🇺🇸 FDA
Pipeline program

Ubamatamab

R4018-ONC-2476

Phase 2 small_molecule active

Quick answer

Ubamatamab for Advanced/Metastatic Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Advanced/Metastatic Non-Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials